Now showing items 1-1 of 1

    • Alemtuzumab CARE-MS II 5-year follow-up 

      Coles, Alasdair John; Cohen, JA; Fox, EJ; Giovannoni, G; Hartung, HP; Havrdova, E; Schippling, S et al. (Wolters Kluwer Health, 2017-08-23)
      Objective: Evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. Methods: In the 2-year CARE-MS II study (NCT00548405), ...